Recent share performance and business snapshot

With no single headline event driving Inspire Medical Systems (INSP) today, attention turns to how the stock’s recent performance and business profile line up for investors watching the name.

The share price closed at US$56.35, with a 1 day return of 4.0%, a flat move over the past week, an 8.2% gain over the past month, and a 29.0% decline over the past 3 months.

Over longer periods, total returns have been negative, including a 38.9% decline year to date, 64.4% over 1 year, 79.0% over 3 years, and 76.6% over 5 years, highlighting meaningful volatility for long term holders.

Inspire Medical Systems focuses on minimally invasive solutions for obstructive sleep apnea, with US$911.981 million in revenue, US$145.422 million in net income, and a market capitalization of about US$1.56b.

The recent 1 day share price return of 4.0% and 1 month share price return of 8.2% sit against a much weaker backdrop, with the year to date share price return and 1 year total shareholder return both showing large declines. This suggests that short term momentum has picked up while longer term performance remains under pressure.

If you are reassessing your healthcare exposure after Inspire Medical Systems recent moves, it can be useful to see what else is out there through the 34 healthcare AI stocks

After a long stretch of weak returns, Inspire Medical Systems now trades at a discount to both some intrinsic estimates and analyst targets. This raises a key question: is this a reset that opens a buying opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 29% Undervalued

Inspire Medical Systems most followed narrative sets a fair value of about $79.42 per share, implying a sizeable gap to the last close at $56.35 and putting the focus on what would need to happen for that gap to close.

The recent delay in transitioning centers to the Inspire V next-generation system, including slower onboarding, delayed SleepSync implementation, and the Medicare billing update, are transitory issues; as these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent-up demand is realized.

Curious what sits behind a higher fair value with slower forecast earnings and revenue growth and a lower future profit margin than today? The narrative leans heavily on one core assumption about how much investors will pay for each dollar of earnings several years out. The detailed model also blends in specific expectations around reimbursement, volume ramp and share count that are not obvious from headline numbers.

Result: Fair Value of $79.42 (UNDERVALUED)

However, there is still meaningful risk that a slower Inspire V rollout and ongoing reimbursement uncertainty, including questions about physician fees, could keep pressure on revenue and earnings expectations.

Next Steps

With sentiment mixed and the recent reset fresh in mind, it makes sense to look at the full picture quickly and then decide where you stand. To see what is driving some investors optimism, review the 3 key rewards.

Looking for more investment ideas?

If Inspire Medical Systems is on your radar, do not stop there; broaden your watchlist now so you are not late to the next opportunity.

• Spot potential turnaround candidates by scanning 27 elite penny stocks with strong financials that already show stronger financial footing than many peers.
• Seek quality at a discount by using the 54 high quality undervalued stocks that screens for companies pairing solid fundamentals with attractive pricing.
• Prioritise resilience by checking the 74 resilient stocks with low risk scores to see stocks with lower overall risk scores that may better fit a cautious approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.